Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of IPH 2201 monotherapy in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the head and neck.

Next Previous
Trial Profile

Phase II trial of IPH 2201 monotherapy in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the head and neck.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Monalizumab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Innate Pharma

Most Recent Events

  • 19 Feb 2015 According to Innate Pharma media release, first patient in this trial was treated in December 2014.
  • 19 Feb 2015 According to Innate Pharma media release, status changed from not yet recruiting to recruiting.
  • 17 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top